Treatment of Refractory Langerhans Cell Histiocytosis (LCH) With a Combination of 2-Chlorodeoxyadenosine and Cytosine Arabinoside
- 1 January 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Pediatric Hematology/Oncology
- Vol. 31 (1), 53-56
- https://doi.org/10.1097/mph.0b013e31817e4a32
Abstract
The combination of 2-chlorodeoxyadenosine (2-CDA) and cytosine arabinoside (Ara-C) has been shown to be effective in children with refractory Langerhans cell histiocytosis (LCH). We have treated 5 patients with recurrent LCH with 2-CDA/Ara-C chemotherapy and closely followed immune and hematopoietic function. These patients display a decline in the absolute CD4, CD8, and natural killer cell number, decrease in the CD4/CD8 ratio. Septic events, including pneumocystis infection were present after most of the treatment courses (15/21). These data suggest that 2-CDA /Ara-C, should be considered in resistant and relapsed pediatric patients with LCH with high-risk multiorgan involvement. Consequent profound prolonged combined immune deficiency and myelosupression should be anticipated.Keywords
This publication has 9 references indexed in Scilit:
- Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunctionEuropean Journal Of Cancer, 2005
- Predictors of outcome in children with Langerhans cell histiocytosisPediatric Blood & Cancer, 2005
- Efficacy of continuous infusion 2‐CDA (cladribine) in pediatric patients with Langerhans cell histiocytosisPediatric Blood & Cancer, 2004
- Gastrointestinal Involvement in Disseminated Langerhans Cell Histiocytosis (LCH) With Durable Complete Response to 2-Chlorodeoxyadenosine and High-Dose CytarabineJournal of Pediatric Hematology/Oncology, 2003
- 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell HistiocytosisMayo Clinic Proceedings, 2003
- Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorMedical and Pediatric Oncology, 2002
- Treatment of children with Langerhans cell histiocytosis with 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 2002
- Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the Histiocyte Society and review of the literatureMedical and Pediatric Oncology, 1999
- Langerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative DiseaseNew England Journal of Medicine, 1994